Fluoroquinolones and risk of Achilles tendon disorders: case-control studyBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7349.1306 (Published 01 June 2002) Cite this as: BMJ 2002;324:1306
- P D van der Linden, researchera,
- M C J M Sturkenboom, researchera,
- R M C Herings, associate professorb,
- H G M Leufkens, professorb,
- B H Ch Stricker, professor (email@example.com)a
- a Pharmaco-epidemiology Unit, Department of Epidemiology & Biostatistics and Internal Medicine, Erasmus Medical Centre Rotterdam, PO Box 1738, 3000 DR Rotterdam, Netherlands
- b Department of Pharmaco-epidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands
- Correspondence to: B H Ch Stricker
- Accepted 9 January 2002
Fluoroquinolones have been associated with tendon disorders, usually during the first month of treatment,1–5 but the epidemiological evidence is scanty. We did a nested case-control study among users of fluoroquinolones in a large UK general practice database to study the association with Achilles tendon disorders.
Participants, methods, and results
We obtained data from the IMS Health database (UK MediPlus), which contains data from general practice on consultations, morbidity, prescriptions, and other interventions in a source population of 1-2 million inhabitants. The base cohort consisted of all patients aged 18 years or over who had received a fluoroquinolone. We excluded people with a history of Achilles tendon disorders, cancer, AIDS, illicit drug use, or alcohol misuse. We identified potential cases by reviewing patient profiles and clinical data and excluded tendon disorders due to direct trauma. We randomly sampled a group of 10 000 control patients from the study cohort.
We defined four categories of exposure to …